Loading
ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Skin cancer, Ovarian cancer and 3 more.
ATP-dependent 3'-5' DNA helicase/translocase. Binds dsDNA rather than ssDNA, unzipping it in a translocase rather than classical helicase activity. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Immune Checkpoint Inhibitor. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.44, somatic mutation 0.85). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Cervical Squamous Cell Carcinoma, Melanoma.
In plain words · ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Skin cancer, Ovarian cancer and 3 more.
ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Skin cancer, Ovarian cancer and 3 more.
ATP-dependent 3'-5' DNA helicase/translocase. Binds dsDNA rather than ssDNA, unzipping it in a translocase rather than classical helicase activity.
No product in this corpus aims at ERCC3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Germline variant: UniProt lists Xeroderma pigmentosum complementation group B (XP-B) under involvement in disease, and the record is a tumour suppressor; the medicines linked to it act through the loss (synthetic lethality) or use the variant to pick patients. HPA ERCC3: RNA low tissue specificity; high antibody staining in 29 normal tissues; highest cancer staining head and neck cancer (4 of 4 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Cervical cancer, Skin cancer (all types), Ovarian cancer, Colorectal cancer, Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (xeroderma pigmentosum group B). (Rule 2 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P19447; Human Protein Atlas ERCC3 tissue; Open Targets ENSG00000163161 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Weeda et al, Mol. Cell. Biol, 1990, "Molecular cloning and biological characterization of the human excision repair gene ERCC-3". Source.
Sources: HGNC HGNC:3435 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P19447 (protein name, function text, keywords and locations (REST API)); CIViC gene ERCC3 (3 evidence items, 0 assertions, 1 variants; diseases: Melanoma, Lung Non-small Cell Carcinoma, Cancer (GraphQL API, CC0)); Open Targets ENSG00000163161 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: colorectal cancer 0.52, ovarian cancer 0.53, melanoma 0.55, skin cancer 0.54 (GraphQL API, CC0)); IntOGen ERCC3 (driver in 2 cohorts (Act 0, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
ATP-dependent 3'-5' DNA helicase/translocase. Binds dsDNA rather than ssDNA, unzipping it in a translocase rather than classical helicase activity. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex. When complexed to CDK-activating kinase (CAK), involved in RNA transcription by RNA polymerase II. The ATPase activity of XPB/ERCC3, but not its helicase activity, is required for DNA opening; it may wrap around the damaged DNA wedging it open, causing localised melting that allows XPD/ERCC2 helicase to anchor. In transcription, TFIIH has an essential role in transcription initiation. Location: Nucleus (UniProt). Locus 2q14.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Cervix, Endometrium, Epididymis, Heart muscle, Lung, Prostate.
Medium only: endometrial cancer.
HPA ERCC3 tissue · HPA ERCC3 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ERCC3" OR ABSTRACT:"ERCC3" OR TITLE:"ERCC excision repair 3, TFIIH core complex helicase subunit" OR ABSTRACT:"ERCC excision repair 3, TFIIH core complex helicase subunit" OR TITLE:"General transcription and DNA repair factor IIH helicase/translocase subunit XPB" OR ABSTRACT:"General transcription and DNA repair factor IIH helicase/translocase subunit XPB" OR TITLE:"BTF2" OR ABSTRACT:"BTF2" OR TITLE:"RAD25" OR ABSTRACT:"RAD25" OR TITLE:"Ssl2" OR ABSTRACT:"Ssl2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ERCC3, not a curated reading list.